Treatment‐resistant depression: where to find hope?
World Psychiatry September 15, 2023 Daniel Souery 2 citations
convincing phase 3 programme leading to eventual approval of psilocybin as a medicine.We are not there yet.
Daniel Souery
2 papers in the library · 86 citations · publishing 2020-2023
Papers
Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance
The World Journal of Biological Psychiatry November 3, 2020 Siegfried Kasper, Wiesław Jerzy Cubała, Andrea Fagiolini et al. 84 citations
OBJECTIVES: -methyl-d-aspartate (NMDA) glutamate receptor antagonist, is a novel, fast-acting option in this patient population. This manuscript provides expert guidance on the practicalities of using esketamine nasal spray. METHODS: A group of six European experts in major depressive disorder (MDD) and TRD, with clinical experience of treating patients with esketamine nasal spray, first...
DOI: 10.1080/15622975.2020.1836399 (opens in new tab)
Treatment-resistant depression
Major depressive disorder
Nasal spray
Depression economics
+4